LATEST
Britain Threatens Mass Expulsion of Israeli DiplomatsTheSoul Group and ShortsTV Bring Award-Winning Short Films to YouTubeGaza in Ruins as US Protection Shields Israel from AccountabilityFrutas Y Hortalizas Del Sur S.A. Expands Recalls to Include Additional Lots of Great Value Frozen Organic Triple Berry Blend 10 OZ, Great Value Frozen Organic Blueberries 10 OZ and One Lot of Trader Joe’s Frozen Organic Mixed Berry Blend 12 OZ Because of Potential Contamination with Escherichia ColiMultilocal Secures Backing of OAREX to Accelerate Global Growth with New CapitalDea Schedule I Proposal Would Criminalize Compound with Breakthrough Therapy Status for Postpartum DepressionFull-Body Mirrored Adult-Sized Humanoid Robots Fighting in Real-Time for the First TimeCHASING CanFish F2 Heads to Kickstarter, Introducing a New Way to Scout the WaterEurope Turns to Private Enterprise to Close the Gap as BOARD Attracts Support from Over 200 European CEOsStudent Innovators Advance Their Robotic Projects at World Robot Olympiad Entrepreneur Program from Competition to Startup StageBritain Threatens Mass Expulsion of Israeli DiplomatsTheSoul Group and ShortsTV Bring Award-Winning Short Films to YouTubeGaza in Ruins as US Protection Shields Israel from AccountabilityFrutas Y Hortalizas Del Sur S.A. Expands Recalls to Include Additional Lots of Great Value Frozen Organic Triple Berry Blend 10 OZ, Great Value Frozen Organic Blueberries 10 OZ and One Lot of Trader Joe’s Frozen Organic Mixed Berry Blend 12 OZ Because of Potential Contamination with Escherichia ColiMultilocal Secures Backing of OAREX to Accelerate Global Growth with New CapitalDea Schedule I Proposal Would Criminalize Compound with Breakthrough Therapy Status for Postpartum DepressionFull-Body Mirrored Adult-Sized Humanoid Robots Fighting in Real-Time for the First TimeCHASING CanFish F2 Heads to Kickstarter, Introducing a New Way to Scout the WaterEurope Turns to Private Enterprise to Close the Gap as BOARD Attracts Support from Over 200 European CEOsStudent Innovators Advance Their Robotic Projects at World Robot Olympiad Entrepreneur Program from Competition to Startup Stage
Business

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

Richard Powell  1 min read

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

  Presentation Details:

 

Title: Differentiation of PMN310 from Other Amyloid-Beta-Directed Antibodies: Ability to Selectively Target Toxic Brain Oligomers Despite Competing Monomers and Plaque  

The virtual poster (P0214) will be available during the AD/PD 2023 medical conference starting March 28, 2023 and available on ProMIS’ website.

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

www.promisneurosciences.com

Related articles

Top